{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:23:16Z","timestamp":1790461396156,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.urolonc.2015.05.018","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T19:22:34Z","timestamp":1434396154000},"page":"413-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Quality of life among testis cancer survivors"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-9303","authenticated-orcid":false,"given":"Timothy","family":"Gilligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2015.05.018_bib1","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2005.08.048","article-title":"Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer","volume":"23","author":"Mykletun","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib2","first-page":"251","article-title":"Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events","volume":"14","author":"Fleer","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib3","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.ejca.2004.03.020","article-title":"Quality of life and stress response symptoms in long-term and recent spouses of testicular cancer survivors","volume":"40","author":"Tuinman","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib4","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1200\/JCO.2008.19.6931","article-title":"Health-related quality of life in long-term survivors of testicular cancer","volume":"27","author":"Rossen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.urology.2009.09.053","article-title":"The effects of testicular cancer treatment on health-related quality of life","volume":"75","author":"Vidrine","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2015.05.018_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12032-014-0043-3","article-title":"Sexual satisfaction, anxiety, depression and quality of life in testicular cancer survivors","volume":"31","author":"Alacacioglu","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.urolonc.2005.03.004","article-title":"Quality of life in survivors of testicular cancer","volume":"23","author":"Dahl","year":"2005","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib8","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s11136-011-9907-6","article-title":"Quality of life among testicular cancer survivors: a case-control study in the United States","volume":"20","author":"Kim","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.urolonc.2015.05.018_bib9","first-page":"476","article-title":"Quality of life of survivors of testicular germ cell cancer: a review of the literature","volume":"12","author":"Fleer","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib10","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/jco.2006.24.18_suppl.4508","article-title":"Long-term non-cancer mortality among 39,657 one-year testicular cancer survivors","volume":"24","author":"Fossa","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib11","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/jnci\/dji278","article-title":"Second cancers among 40,576 testicular cancer patients: focus on long-term survivors","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2015.05.018_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JCO.2002.20.1.73","article-title":"Quality of life in long-term survivors of testicular cancer: a population-based case-control study","volume":"20","author":"Joly","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib13","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.eururo.2007.05.012","article-title":"The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era","volume":"52","author":"Wiechno","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib14","first-page":"1","article-title":"The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors","author":"Grov","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib15","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/pon.3323","article-title":"The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study","volume":"22","author":"Smith","year":"2013","journal-title":"Psychooncology"},{"key":"10.1016\/j.urolonc.2015.05.018_bib16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/j.1464-410X.2012.11696.x","article-title":"Psychological needs when diagnosed with testicular cancer: findings from a population-based study with long-term follow-up","volume":"111","author":"Skoogh","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2015.05.018_bib17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO.2003.08.163","article-title":"Fatigue, anxiety, and depression in long-term survivors of testicular cancer","volume":"21","author":"Fossa","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib18","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2005.05.061","article-title":"Study of anxiety disorder and depression in long-term survivors of testicular cancer","volume":"23","author":"Dahl","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jad.2009.06.035","article-title":"Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality","volume":"122","author":"Eberhard","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1016\/j.urolonc.2015.05.018_bib20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/pon.1437","article-title":"Fear of recurrence in long-term testicular cancer survivors","volume":"18","author":"Skaali","year":"2009","journal-title":"Psychooncology"},{"key":"10.1016\/j.urolonc.2015.05.018_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpsychores.2008.01.002","article-title":"Chronic cancer-related fatigue in long-term survivors of testicular cancer","volume":"64","author":"Orre","year":"2008","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.urolonc.2015.05.018_bib22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.bbi.2009.04.003","article-title":"Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue","volume":"23","author":"Orre","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.urolonc.2015.05.018_bib23","doi-asserted-by":"crossref","first-page":"876","DOI":"10.6004\/jnccn.2014.0082","article-title":"Survivorship: fatigue, version 1.2014","volume":"12","author":"Denlinger","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2015.05.018_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue\u2014mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib25","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1200\/JCO.2013.53.4495","article-title":"Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation","volume":"32","author":"Bower","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib26","doi-asserted-by":"crossref","first-page":"E326","DOI":"10.1188\/14.ONF.E326-E342","article-title":"Are exercise programs effective for improving health-related quality of life among cancer survivors? A systematic review and meta-analysis","volume":"41","author":"Mishra","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.urolonc.2015.05.018_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1188\/14.CJON.S3.38-58","article-title":"Putting evidence into practice: an update of evidence-based interventions for cancer-related fatigue during and following treatment","volume":"18","author":"Mitchell","year":"2014","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.urolonc.2015.05.018_bib28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/PPO.0000000000000069","article-title":"Review of clinical trials of pharmacologic interventions for cancer-related fatigue: focus on psychostimulants and steroids","volume":"20","author":"Yennurajalingam","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.urolonc.2015.05.018_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1188\/07.CJON.99-113","article-title":"Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment","volume":"11","author":"Mitchell","year":"2007","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.urolonc.2015.05.018_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jphys.2014.08.019","article-title":"Supervised exercise reduces cancer-related fatigue: a systematic review","volume":"61","author":"Meneses-Echavez","year":"2015","journal-title":"J Physiother"},{"key":"10.1016\/j.urolonc.2015.05.018_bib31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/sj.bjc.6603899","article-title":"Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up","volume":"97","author":"Gielissen","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib32","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1200\/JCO.2006.06.8270","article-title":"Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial","volume":"24","author":"Gielissen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1200\/JCO.2011.37.2979","article-title":"Web-based tailored education program for disease-free cancer survivors with cancer-related fatigue: a randomized controlled trial","volume":"30","author":"Yun","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib34","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/bjc.1998.226","article-title":"Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer","volume":"77","author":"Bokemeyer","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/annonc\/mdf058","article-title":"Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer","volume":"13","author":"Strumberg","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.radonc.2012.10.012","article-title":"Radiation-induced neuropathy in cancer survivors","volume":"105","author":"Delanian","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib37","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djp413","article-title":"Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors","volume":"101","author":"Brydoy","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2015.05.018_bib38","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/cncr.24981","article-title":"Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer","volume":"116","author":"Glendenning","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib39","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9","article-title":"Platinum organ toxicity and possible prevention in patients with testicular cancer","volume":"83","author":"Hartmann","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib40","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2003.02.075","article-title":"Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group\/Medical Research Council Testicular Cancer Study Group (30941\/TE20)","volume":"21","author":"Fossa","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib41","doi-asserted-by":"crossref","first-page":"e106485","DOI":"10.1371\/journal.pone.0106485","article-title":"Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy","volume":"9","author":"Kelley","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2015.05.018_bib42","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1038\/srep06370","article-title":"Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl\/6 mice","volume":"4","author":"Boehmerle","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2015.05.018_bib43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/02841860902806609","article-title":"Persistent neuropathy after treatment with cisplatin and oxaliplatin","volume":"48","author":"Brouwers","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib44","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies","volume":"44","author":"Wolf","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib45","first-page":"CD005228","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","volume":"3","author":"Albers","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.urolonc.2015.05.018_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2009-S501","article-title":"Assessment of cancer-related neuropathy and neuropathic pain","volume":"15","author":"Cleeland","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2015.05.018_bib47","first-page":"1134","article-title":"A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results","volume":"14","author":"Argyriou","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib48","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2003.05.139","article-title":"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy","volume":"21","author":"Pace","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib49","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.0b013e3181d5279e","article-title":"Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial","volume":"74","author":"Pace","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.urolonc.2015.05.018_bib50","first-page":"1769","article-title":"The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial","volume":"19","author":"Kottschade","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib51","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2015.05.018_bib52","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib53","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2015.05.018_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.autrev.2013.12.001","article-title":"Raynaud\u2019s phenomenon: from molecular pathogenesis to therapy","volume":"13","author":"Prete","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.urolonc.2015.05.018_bib55","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-015-0443-1","article-title":"A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial","author":"Boekhout","year":"2015","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.urolonc.2015.05.018_bib56","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/bjc.2014.505","article-title":"Survivorship care plans in cancer: a systematic review of care plan outcomes","volume":"111","author":"Brennan","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2015.05.018_bib57","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1200\/JCO.2011.36.8373","article-title":"Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer","volume":"29","author":"Grunfeld","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143915002422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143915002422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:07:02Z","timestamp":1761041222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143915002422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1078143915002422"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2015.05.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life among testis cancer survivors","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2015.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}